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Post-Deployment Balloon Dilation After
Transcatheter Aortic Valve Replacement
Can We Predict and Prevent?*Paolo Raggi, MDK halique et al. (1) report in this issue of JACC:Cardiovascular Interventions on the impactthat calciﬁcation of the aortic valve appa-
ratus may have on the outcome of transcatheter
aortic valve replacement (TAVR). In this single-
center analysis, the authors showed that calciﬁcation
at any level, from the outﬂow track to the aortic
valve annulus and leaﬂets, is a predictor of paravalv-
ular aortic regurgitation (PVR) and the need to
perform post-deployment balloon dilations, a surro-
gate marker of PVR. Because the occurrence of PVR
is a predictor of subsequent mortality (2), it seems
worth predicting and preventing it. Some conﬂicting
information has been published in prior literature;
some authors attributed the risk of PVR to eitherSEE PAGE 885annular or leaﬂet calciﬁcation; some supported the
notion that asymmetry of leaﬂet calciﬁcation is an
important predictor, whereas others disputed it;
some predicted that annular calciﬁcation is more
important than commissural or leaﬂet calciﬁcation,
and so on. The current report (1) puts to rest the con-
troversy by showing that no matter where the calciﬁ-
cation is located, it is a predictor of PVR. So calcium is
doing it again! Heavy calciﬁcation of the aortic
annulus is a warning for the surgeon that the native
valve will be much harder to remove without damage* Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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Edmonton, Alberta, Canada. Dr. Raggi has reported that he has no re-
lationships relevant to the contents of this paper to disclose.to the aortic wall and that a prosthetic valve will not
be easily ﬁtted and sutured in place. Calciﬁcation of
the aorta (porcelain aorta) is a harbinger of complica-
tions if clamping or puncturing were to be attempted.
Dense calciﬁcation of the coronary arteries predis-
poses to development of dissection during interven-
tional procedures, and is associated with more
frequent restenosis. Are all these unfavorable out-
comes the result of a mere mechanical problem, one
of asymmetry, distortion, and loss of elasticity?
Or are there other reasons for such instability? Calci-
ﬁcation of the aortic valve and aortic root resembles
very closely the process of atherosclerosis, with
disruption of the basal membrane, inﬁltration of
inﬂammatory cells, deposition of lipids, and accom-
panying calciﬁcation (3,4). Calciﬁcation is an active
process similar to bone formation, with lamellar
bone, hematopoietic elements, and active bone
remodeling seen in the context of the damaged
valvular tissue (5,6). Several epidemiological studies
showed that independent risk factors for aortic valve
sclerosis are the same as those for atherosclerosis:
age, male sex, serum lipoprotein(a), and low-density
lipoprotein cholesterol levels, hypertension, and
smoking (3,4). Dweck et al. (7) showed that inﬂamma-
tion in a calciﬁed aortic valve can be demonstrated by
positron emission tomography–computed tomogra-
phy imaging. So we are dealing, not with an amor-
phous, inert, and dystrophic tissue, but with a
tissue subject to continuous dynamic changes? The
immediate unfavorable outcome of a valve deploy-
ment may be dictated by mechanical issues, but the
long-term outcome is likely to be dictated in part
by the underlying active biological processes. One
also wonders whether the balloon valvuloplasty
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896performed before TAVR perturbs a very delicate
biomechanical balance, inducing further instability
in an environment already architectonically chal-
lenged. Unfortunately, there are no effective mechan-
ical or pharmacological interventions to reduce the
bulk of calciﬁcation of the aortic valve, and statins
were conclusively shown to have no effect on
valvular calciﬁcation and the progression of stenosis
(8,9). In fact, in vitro cellular experiments suggested
a potentially procalcifying effect of statins (10).
Hence, as of today, we may be able to predict the
development of PVR, but we might not be able to
prevent it. The very recent guidelines on treatment
of valvular heart disease (11) indicate that TAVR is
an acceptable alternative to surgical intervention in
patients with a prohibitive risk of surgery (>50%
mortality) and a predicted survival >12 months after
TAVR (Class I, Level of Evidence: B) and in high sur-
gical risk patients (>10% mortality risk; Class IIa,
Level of Evidence: B). However, if a patient has a
very high surgical risk, but presents with severe
calciﬁcation of the aortic valve apparatus, which in
turn puts that patient at risk of developing
moderate-to-severe PVR, and PVR increases the
30-day and 1-year mortality 2- to 3-fold (2), are we
still justiﬁed to consider TAVR? Once again, the
ever-correct conclusion is that a careful selection of
the most suitable patient for the most appropriate
procedure is the desirable way to proceed. How
does the paper by Khalique et al. (1) help us in this
regard? For one thing, it refutes the opinion that
one location is worse than another as far as valvular
calciﬁcation is concerned and refocuses the attention
on the extent of calciﬁcation rather than geographical
considerations. Where the article by Khalique et al.
falls short, however, is the lack of an indication of
“how much is too much,” that is, a threshold beyond
which the risk of moderate-to-severe PVR is too
high to attempt the procedure. A few other consider-
ations are also important. The study was performed
at a single center by expert operators, and only1 type of valve was implanted (either of 2 balloon-
expandable Sapien valves [Edwards Lifesciences,
Irvine, California]). In a recent meta-analysis, Athap-
pan et al. (2) demonstrated that the expected rate of
moderate-to-severe PVR is about 12% overall, but the
rate is higher for the self-expandable CoreValves
(Medtronic, Minneapolis, Minnesota) than the Sapien
valves (16.0% vs. 9.1%, p ¼ 0.005). Additionally,
the investigators of the current report (1) did not
observe any severe PVR (expected in 1.5% to 2% of
procedures) and reported moderate PVR in only 9
patients (6%); they further included mild PVR in
their analyses of post-procedural complications.
According to the large meta-analysis by Athappan
et al. (2), mild PVR showed only a trend as a predic-
tor of mortality once sensitivity analyses were con-
ducted by excluding outlier studies and switching
meta-analytical methods from random to ﬁxed
effect. So are we to be alarmed and forewarned of
the dangers of performing TAVR in patients with
heavy calciﬁcation of the valvular apparatus?
More knowledge needs to be accumulated regarding
the threshold of calciﬁcation that represents a warning
sign for development of important post-procedural
complications, and whether mild PVR constitutes
a true risk. Appropriate pre-procedural planning
for TAVR should include careful annulus sizing, quan-
tiﬁcation of calcium burden, and assessment of left
ventricular outﬂow tract and annulus asymmetry by
computed tomography imaging. An accurate assess-
ment of these variables will inform the selection of
the most appropriate valve (self-expanding vs.
balloon-expanding) to implant, as well as the best
patient candidate for TAVR, to improve operative re-
sults as well as patient outcomes.
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